Will AstraZeneca continue to outperform in 2019?

Andy Ross sees plenty to be upbeat about at AstraZeneca plc (LON:AZN) that he thinks could keep it beating the FTSE 100 (INDEXFTSE: UKX) this year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Many investors will have been burned in 2018 as the FTSE 100 fell by around 12%, however, some companies bucked the trend and saw their share prices rising despite that overall market fall and despite Brexit concerns.

AstraZeneca (LSE: AZN) was one such company. Over the course of 2018, the share price rose by over 13.5%, while FTSE 100 peer GlaxoSmithKline also grew its share price by 11%. This shows above all how investors were seeking defensive stocks to help shield them from the increased market volatility and political uncertainty.

The conditions that caused investors so much anxiety in 2018 (Brexit, trade wars) are likely to persist into at least the first part of 2019 and that should benefit defensive companies in industries like energy and pharmaceuticals. Even over a longer timeframe, AstraZeneca should be able to provide market-beating returns to investors due to its drug pipeline and dividend.

A sustainable, growing dividend

Given that its share price has been rising, its dividend yield isn’t the highest, but in many ways, this is a positive sign as a low P/E and high dividend yield can be a warning sign of danger ahead. Investors should take confidence in the firm’s sustainable 3.5% dividend yield. The dividend cover of around 1.5x (and the fact that the dividend has been held while the drugs pipeline is rebuilt after a series of patent expiries) should reward investors going forward. Furthermore, the stated aim of the company’s management is for the dividend to be progressive, which means that as the company makes more profit, the dividend should grow. 

Finding the next blockbusters

Overall AstraZeneca has around 150 projects in its pipeline. The oncology unit where the company is focusing more and more of its resources has 34 pipeline treatments that have already been submitted for approvals or are at phase three of the approvals process, meaning there is significant potential for finding the next blockbuster drug. Other treatment areas, including cardiovascular and metabolic diseases and respiratory, also have many drugs in the pipeline that are edging close to final approvals. 

Given the huge R&D expenditure and focus on specific therapy areas as well as building up its pipeline, it seems likely the firm has a good chance of finding blockbusters to replace drugs that are no longer protected by patents from generic rivals.

Attractive industry, attractive business

Margins in the pharmaceutical industry tend to be very high and AstraZeneca is no exception to this. The H1 results for 2018 showed the gross margin was a very healthy 78.6%, although it had dropped slightly. The company also highlighted that new medicines and emerging markets were performing particularly well and were sources of growth, which is an encouraging sign for investors. 

Full-year results are out next month, and this will provide the first insight into how 2019 might look for the company. Based on the information we have to date and the share price performance, investors ought to be optimistic about the prospects for the company over the next 12 months and beyond.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Andy Ross has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s how I’d aim for a ton of passive income from £20k in an ISA

To get the best passive income from an ISA, I think we need to balance risk with the potential rewards.…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

2 FTSE 100 stocks I’d buy as the blue-chip index hits record highs

This Fool takes a look at a pair of quality FTSE 100 stocks that appear well-positioned for future gains, despite…

Read more »

Satellite on planet background
Small-Cap Shares

Here’s why AIM stock Filtronic is up 44% today

The share price of AIM stock Filtronic has surged on the back of some big news in relation to its…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

At a record high, there can still be bargain FTSE 100 shares to buy!

The FTSE 100 closed at a new all-time high this week. Our writer explains why there might still be bargain…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

After profits plunge 28%, should investors consider buying Lloyds shares?

Lloyds has seen its shares wobble following the release of its latest results. But is this a chance for investors…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

Something’s changed in a good way for Reckitt in Q1, and the share price may be about to take off

With the Reckitt share price near 4,475p, is this a no-brainer stock? This long-time Fool takes a closer look at…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

This new boost in assets might just get the abrdn share price moving again

The abrdn share price has lost half its value in the past five years. But with investor confidence returning, are…

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

As revenues rise 8%, is the Croda International share price set to bounce back?

The latest update from Croda International indicates that sales are starting to recover from the end of 2023, so is…

Read more »